<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276509</url>
  </required_header>
  <id_info>
    <org_study_id>A7281006</org_study_id>
    <secondary_id>2010-023437-30</secondary_id>
    <secondary_id>OPERA</secondary_id>
    <nct_id>NCT01276509</nct_id>
  </id_info>
  <brief_title>Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease</brief_title>
  <acronym>OPERA</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adults with Crohn's disease that is clinically active despite conventional treatment will be
      eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental
      drug) or placebo (inactive drug). Disease activity will be measured every two weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2011</start_date>
  <completion_date type="Actual">October 9, 2015</completion_date>
  <primary_completion_date type="Actual">February 7, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate</measure>
    <time_frame>Week 8 and week 12</time_frame>
    <description>Crohn's Disease Activity Index (CDAI) is a number which consists of information collected from a 7-day diary from the participants regarding symptoms. Remission is considered a score of 150 or less. Active disease is considered 200 or greater. A response to therapy is considered a decline in CDAI score of 70-points from baseline. CDAI response rate at week 8 and week 12 was measured between the investigational product group and the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of PFâ€‘00547659 Dose Levels Versus Placebo</measure>
    <time_frame>Week 0-12</time_frame>
    <description>Number of participants with adverse events (AEs), withdrawals due to AEs and Serious AEs (SAEs) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) - PF-00547659 Dose Levels Versus Placebo</measure>
    <time_frame>Week 0-12</time_frame>
    <description>Number of adverse events (all causalities and treatment related) was reported between the investigational product groups and the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Crohn's Disease Activity Index (CDAI) Remission</measure>
    <time_frame>Weeks 8 and week 12</time_frame>
    <description>Percentage of participants with a CDAI remission (defined as a CDAI reduction to &lt;150 points).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's Disease Activity Index (CDAI)-70 Response Rates Over Time</measure>
    <time_frame>Week 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Percentage of participants with Crohn's Disease Activity Index (CDAI)-70 response were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer</measure>
    <time_frame>Week 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Percentage of participants with Crohn's Disease Activity Index (CDAI)-100 response were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Assessment of Anti-drug Antibodies (ADAs)</measure>
    <time_frame>Day 1, Week 4, Week 8, Week 12, Week 20, Week 28, Week 36</time_frame>
    <description>Confirmed cumulative incidence of anti-drug antibodies development to PF-00547659</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)</measure>
    <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
    <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to area under the concentration-time profile (AUC), clearance (CL) and half life were estimated using data pooled from both typical and additional PK groups. AUCinf is area under the concentration time profile from time zero extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau)</measure>
    <time_frame>Day 1, 14, and 28</time_frame>
    <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. AUCtau is area under the concentration time profile from time zero to time tau, the dosing interval, where tau = 672 hours (4 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
    <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Cmax is maximum observed concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)</measure>
    <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
    <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Tmax is time for Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)</measure>
    <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
    <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Thalf is terminal half life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)</measure>
    <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
    <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. CL/F is apparent clearance.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo-SC Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Dose level 1- SC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Dose level 2-SC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Dose level 3- SC injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00547659 SC injection</intervention_name>
    <description>Placebo delivered SC, 3 doses separated by 4 weeks</description>
    <arm_group_label>Placebo-SC Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00547659 SC injection</intervention_name>
    <description>Drug dose level 1 delivered SC, 3 doses separated by 4 weeks</description>
    <arm_group_label>Drug Dose level 1- SC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00547659 SC injection</intervention_name>
    <description>Drug dose level 2 delivered SC, 3 doses separated by 4 weeks</description>
    <arm_group_label>Drug Dose level 2-SC injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00547659 SC injection</intervention_name>
    <description>Drug dose level 3 delivered SC, 3 doses separated by 4 weeks</description>
    <arm_group_label>Drug Dose level 3- SC injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have failed or are intolerant to anti-TNFs and/or immunosuppressants
             (AZA, 6-MP, and/or MTX).

          -  hsCRP greater than 3mg/L

          -  Ulcerations demonstrated by colonoscopy performed during screening or 8 weeks prior to
             screening

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  Short bowel syndrome due to multiple small bowel resections

          -  Presence of a stoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clopton Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Specialists of Arkansas</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Diagnostic Clinic, P.A.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center-Thornton Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Trials</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Diagnostics</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Gastroenterology Medical Associates, Inc.</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioMark Research Inc.</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of the Rockies</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Gastroenterology Associates</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Clinical Research Foundation</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Endoscopy Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Hospital at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Medical Plaza</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Center for Gastroenterology</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>FL 33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cirtus Ambulartory Surgery Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Specialists</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Medical Research (Administrative Only)</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Digestive Disease Center</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Endoscopy Center (Colonoscopy Only)</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Gastroenterology Group, PC - Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgical Centers of Michigan</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute, West Health Campus</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noran Neurology Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulting Radiology (Xray testing only)</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gastroenterology, P.A.</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgery Center of Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audrain Medical Center</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive and Liver Diseases, Inc.</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital - Investigational Drug Services</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Medi-Research And Management</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Hospital Queens</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Clinical Research Associates, LLP</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nassau Gastroenterology Associates Office Based Surgery</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nassau Gastroenterology Associates, P.C.</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Primary Care, P.C.</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center - Phillip Ambulatory Care Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East side Endoscopy, LLC (for colonscopy testing only)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Endoscopy Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTRC Hospital - UNC Memorial Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Memorial Hospital Endoscopy Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Hospitals Department of Pharmacy</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Hospitals Endoscopy</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillsborough Campus</name>
      <address>
        <city>Hillsborough</city>
        <state>North Carolina</state>
        <zip>27278</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Offices of Dr. Vincent Armenio, M.D.</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharma Resource</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayside Endoscopy Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasadena Gastroenterology Associates, P.A. dba Digestive Health Center</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah HSC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Gastroenterology Associates</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Associates</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien Universitaetsklinik fuer Innere Medizin III</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de LiÃ¨ge - Labo Biologie Clinique</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mouscron</name>
      <address>
        <city>Mouscron</city>
        <zip>7700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4-MHAT</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL Sofiamed OOD,Otdelenie po gastroenterologia</name>
      <address>
        <city>Sofia</city>
        <zip>1979</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Coastal Health - Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Coastal Health - Vancouver Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oshawa Clinic</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Digestive Disease Associates Inc.</name>
      <address>
        <city>Vaughan</city>
        <state>Ontario</state>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hopital Nord Service d'Hepato-Gastroenterologie</name>
      <address>
        <city>Amiens Cedex 01</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Andre</name>
      <address>
        <city>Bordeaux cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon- Essais cliniques</name>
      <address>
        <city>Clichy Cedex</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Archet 2 - CHU de Nice</name>
      <address>
        <city>NICE Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin-Essais Cliniques</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen Cedex 1</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Rangueil</name>
      <address>
        <city>Toulouse cedex 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Berlin Mitte Medizinische Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Doelau gGmbH</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsfrauenklinikum Schleswig-Holstein Medizinische Klinik I, Gastroenterologie/Hepatologie</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis Minden</name>
      <address>
        <city>Minden</city>
        <zip>32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hirosaki National Hospital</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8545</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Takasaki General Medical Center</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <zip>370-0829</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei University Hospital</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University Hospital</name>
      <address>
        <city>Aichi</city>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University College of Medicine, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <state>GR</state>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asker And Baerum Hospital</name>
      <address>
        <city>Gjettum</city>
        <zip>1346</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus</name>
      <address>
        <city>Olso</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovisenberg Diakonale Sykehus</name>
      <address>
        <city>Oslo</city>
        <zip>0440</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im dr. Jana Bizieta w Bydgoszczy Centrum Endoskopii Zabiegowej</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne-Szpital Swietej Rodziny Sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexmedica</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-114</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis Clinic for Gastroenterology and Hepatology</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun</name>
      <address>
        <city>Zemun</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroentero-Hepatologicke centrum THALION, LAMA MEDICAL CARE s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>831 04</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medak s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>851 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologicke a hepatologicke centrum Nitra, KM Management spol. s r.o.</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy group, a.s.</name>
      <address>
        <city>Nove Mesto Nad Vahom</city>
        <zip>915 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parklands Medical Centre</name>
      <address>
        <city>Durban</city>
        <state>Kwa-zulu - Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingsbury Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7708</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Portugal</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7281006&amp;StudyName=Study%20To%20Test%20Whether%20PF-00547659%20Is%20Safe%20And%20Improves%20Disease%20Symptoms%20In%20Patients%20With%20Crohn%27s%20Disease</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <results_first_submitted>October 5, 2016</results_first_submitted>
  <results_first_submitted_qc>March 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2017</results_first_posted>
  <disposition_first_submitted>February 8, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 8, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 25, 2015</disposition_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease Safety Efficacy Pharmacokinetics Pharmacodynamics Crohn's Disease Activity Index (CDAI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In total, 265 participants were randomized and 262 entered the study and received study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PF-00547659 22.5 mg</title>
          <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>PF-00547659 75 mg</title>
          <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>PF-00547659 225 mg</title>
          <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PF-00547659 22.5 mg</title>
          <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>PF-00547659 75 mg</title>
          <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>PF-00547659 225 mg</title>
          <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="68"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="262"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="13.0"/>
                    <measurement group_id="B2" value="34.4" spread="10.7"/>
                    <measurement group_id="B3" value="35.9" spread="11.0"/>
                    <measurement group_id="B4" value="34.4" spread="11.1"/>
                    <measurement group_id="B5" value="35.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>FEMALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MALE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate</title>
        <description>Crohn's Disease Activity Index (CDAI) is a number which consists of information collected from a 7-day diary from the participants regarding symptoms. Remission is considered a score of 150 or less. Active disease is considered 200 or greater. A response to therapy is considered a decline in CDAI score of 70-points from baseline. CDAI response rate at week 8 and week 12 was measured between the investigational product group and the placebo group.</description>
        <time_frame>Week 8 and week 12</time_frame>
        <population>The full analysis set included all randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate</title>
          <description>Crohn's Disease Activity Index (CDAI) is a number which consists of information collected from a 7-day diary from the participants regarding symptoms. Remission is considered a score of 150 or less. Active disease is considered 200 or greater. A response to therapy is considered a decline in CDAI score of 70-points from baseline. CDAI response rate at week 8 and week 12 was measured between the investigational product group and the placebo group.</description>
          <population>The full analysis set included all randomized participants who received at least one dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n =50, 55, 62, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7"/>
                    <measurement group_id="O2" value="60.1"/>
                    <measurement group_id="O3" value="62.7"/>
                    <measurement group_id="O4" value="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n = 51, 49, 61, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0"/>
                    <measurement group_id="O2" value="64.7"/>
                    <measurement group_id="O3" value="57.5"/>
                    <measurement group_id="O4" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3393</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.121</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.149</ci_lower_limit>
            <ci_upper_limit>0.249</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1433</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.117</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.068</ci_lower_limit>
            <ci_upper_limit>0.316</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0922</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.113</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.036</ci_lower_limit>
            <ci_upper_limit>0.335</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3864</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.034</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.117</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.158</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3005</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.117</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.131</ci_lower_limit>
            <ci_upper_limit>0.253</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5385</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.114</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.198</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of PFâ€‘00547659 Dose Levels Versus Placebo</title>
        <description>Number of participants with adverse events (AEs), withdrawals due to AEs and Serious AEs (SAEs) were reported.</description>
        <time_frame>Week 0-12</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of PFâ€‘00547659 Dose Levels Versus Placebo</title>
          <description>Number of participants with adverse events (AEs), withdrawals due to AEs and Serious AEs (SAEs) were reported.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of study medication.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs (all causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with AEs (treatment related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal due to AEs (all causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawal due to AEs (treatment related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs (all causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs (treatment related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AEs) - PF-00547659 Dose Levels Versus Placebo</title>
        <description>Number of adverse events (all causalities and treatment related) was reported between the investigational product groups and the placebo group.</description>
        <time_frame>Week 0-12</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) - PF-00547659 Dose Levels Versus Placebo</title>
          <description>Number of adverse events (all causalities and treatment related) was reported between the investigational product groups and the placebo group.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of study medication.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of AEs (all causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="192"/>
                    <measurement group_id="O3" value="192"/>
                    <measurement group_id="O4" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of AEs (treatment related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Crohn's Disease Activity Index (CDAI) Remission</title>
        <description>Percentage of participants with a CDAI remission (defined as a CDAI reduction to &lt;150 points).</description>
        <time_frame>Weeks 8 and week 12</time_frame>
        <population>The full analysis set included all randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Crohn's Disease Activity Index (CDAI) Remission</title>
          <description>Percentage of participants with a CDAI remission (defined as a CDAI reduction to &lt;150 points).</description>
          <population>The full analysis set included all randomized participants who received at least one dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n = 50, 56, 62, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="23.8"/>
                    <measurement group_id="O3" value="26.9"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n= 51, 49, 61, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="28.5"/>
                    <measurement group_id="O3" value="29.6"/>
                    <measurement group_id="O4" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1234</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.052</ci_lower_limit>
            <ci_upper_limit>0.299</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2378</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.092</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1529</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.100</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.062</ci_lower_limit>
            <ci_upper_limit>0.266</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3661</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.038</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.112</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.146</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3169</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.116</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.136</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference from placebo at week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2755</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.066</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.111</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.116</ci_lower_limit>
            <ci_upper_limit>0.248</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crohn's Disease Activity Index (CDAI)-70 Response Rates Over Time</title>
        <description>Percentage of participants with Crohn's Disease Activity Index (CDAI)-70 response were reported.</description>
        <time_frame>Week 2, 4, 6, 8, 10 and 12</time_frame>
        <population>The full analysis set included all randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Crohn's Disease Activity Index (CDAI)-70 Response Rates Over Time</title>
          <description>Percentage of participants with Crohn's Disease Activity Index (CDAI)-70 response were reported.</description>
          <population>The full analysis set included all randomized participants who received at least one dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n = 64, 60, 63, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="22.8" upper_limit="49.6"/>
                    <measurement group_id="O2" value="22.4" lower_limit="12.9" upper_limit="36.0"/>
                    <measurement group_id="O3" value="33.8" lower_limit="21.6" upper_limit="48.5"/>
                    <measurement group_id="O4" value="35.5" lower_limit="22.9" upper_limit="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 58, 60, 65, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0" lower_limit="24.9" upper_limit="53.2"/>
                    <measurement group_id="O2" value="39.5" lower_limit="26.3" upper_limit="54.4"/>
                    <measurement group_id="O3" value="36.2" lower_limit="23.7" upper_limit="51.0"/>
                    <measurement group_id="O4" value="38.3" lower_limit="25.1" upper_limit="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n =56, 54, 64, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="31.1" upper_limit="60.3"/>
                    <measurement group_id="O2" value="53.4" lower_limit="38.2" upper_limit="67.9"/>
                    <measurement group_id="O3" value="47.5" lower_limit="33.3" upper_limit="62.1"/>
                    <measurement group_id="O4" value="48.0" lower_limit="33.5" upper_limit="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n =50, 55, 62, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" lower_limit="37.2" upper_limit="67.7"/>
                    <measurement group_id="O2" value="60.1" lower_limit="44.9" upper_limit="73.6"/>
                    <measurement group_id="O3" value="62.7" lower_limit="47.9" upper_limit="75.4"/>
                    <measurement group_id="O4" value="47.7" lower_limit="33.1" upper_limit="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n =50, 48, 60, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" lower_limit="52.0" upper_limit="79.7"/>
                    <measurement group_id="O2" value="58.2" lower_limit="42.3" upper_limit="72.6"/>
                    <measurement group_id="O3" value="61.6" lower_limit="46.8" upper_limit="74.6"/>
                    <measurement group_id="O4" value="53.0" lower_limit="37.6" upper_limit="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n = 51, 49, 61, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" lower_limit="46.5" upper_limit="75.3"/>
                    <measurement group_id="O2" value="64.7" lower_limit="48.9" upper_limit="77.8"/>
                    <measurement group_id="O3" value="57.5" lower_limit="42.6" upper_limit="71.2"/>
                    <measurement group_id="O4" value="58.6" lower_limit="43.3" upper_limit="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer</title>
        <description>Percentage of participants with Crohn's Disease Activity Index (CDAI)-100 response were reported.</description>
        <time_frame>Week 2, 4, 6, 8, 10 and 12</time_frame>
        <population>The full analysis set included all randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Crohn's Disease Activity Index (CDAI) -100 Response Rates Over Timer</title>
          <description>Percentage of participants with Crohn's Disease Activity Index (CDAI)-100 response were reported.</description>
          <population>The full analysis set included all randomized participants who received at least one dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n = 64, 60, 63, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="10.6" upper_limit="32.6"/>
                    <measurement group_id="O2" value="18.4" lower_limit="9.9" upper_limit="31.7"/>
                    <measurement group_id="O3" value="20.0" lower_limit="11.0" upper_limit="33.6"/>
                    <measurement group_id="O4" value="18.5" lower_limit="9.9" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 58, 60 ,65, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="17.5" upper_limit="44.6"/>
                    <measurement group_id="O2" value="32.3" lower_limit="20.0" upper_limit="47.5"/>
                    <measurement group_id="O3" value="28.2" lower_limit="17.0" upper_limit="43.0"/>
                    <measurement group_id="O4" value="29.5" lower_limit="17.7" upper_limit="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n =56, 54, 64, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="26.6" upper_limit="56.4"/>
                    <measurement group_id="O2" value="42.6" lower_limit="28.2" upper_limit="58.5"/>
                    <measurement group_id="O3" value="40.4" lower_limit="26.8" upper_limit="55.8"/>
                    <measurement group_id="O4" value="39.3" lower_limit="25.5" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n = 50, 55, 62, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="34.8" upper_limit="66.2"/>
                    <measurement group_id="O2" value="48.3" lower_limit="33.3" upper_limit="63.7"/>
                    <measurement group_id="O3" value="57.0" lower_limit="41.8" upper_limit="71.0"/>
                    <measurement group_id="O4" value="41.4" lower_limit="27.2" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (n = 50, 48, 62, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" lower_limit="37.3" upper_limit="68.5"/>
                    <measurement group_id="O2" value="47.4" lower_limit="31.8" upper_limit="63.5"/>
                    <measurement group_id="O3" value="50.9" lower_limit="35.9" upper_limit="65.7"/>
                    <measurement group_id="O4" value="43.6" lower_limit="28.7" upper_limit="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n = 51, 49, 61, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="40.1" upper_limit="70.7"/>
                    <measurement group_id="O2" value="47.7" lower_limit="32.2" upper_limit="63.7"/>
                    <measurement group_id="O3" value="53.8" lower_limit="38.7" upper_limit="68.4"/>
                    <measurement group_id="O4" value="44.4" lower_limit="29.6" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Assessment of Anti-drug Antibodies (ADAs)</title>
        <description>Confirmed cumulative incidence of anti-drug antibodies development to PF-00547659</description>
        <time_frame>Day 1, Week 4, Week 8, Week 12, Week 20, Week 28, Week 36</time_frame>
        <population>The safety analysis set included all participants who receive at least 1 dose of PF-00547659. Participants in placebo arm were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Assessment of Anti-drug Antibodies (ADAs)</title>
          <description>Confirmed cumulative incidence of anti-drug antibodies development to PF-00547659</description>
          <population>The safety analysis set included all participants who receive at least 1 dose of PF-00547659. Participants in placebo arm were not included in this analysis.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n =46, 52, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n = 55, 52, 55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n = 44, 47, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n = 47, 51, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n = 4, 3, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n = 8, 1, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n = 6, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)</title>
        <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to area under the concentration-time profile (AUC), clearance (CL) and half life were estimated using data pooled from both typical and additional PK groups. AUCinf is area under the concentration time profile from time zero extrapolated to infinite time.</description>
        <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
        <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf)</title>
          <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to area under the concentration-time profile (AUC), clearance (CL) and half life were estimated using data pooled from both typical and additional PK groups. AUCinf is area under the concentration time profile from time zero extrapolated to infinite time.</description>
          <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
          <units>Âµgâ€¢hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="615300" spread="63"/>
                    <measurement group_id="O2" value="4464000" spread="28"/>
                    <measurement group_id="O3" value="13760000" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau)</title>
        <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. AUCtau is area under the concentration time profile from time zero to time tau, the dosing interval, where tau = 672 hours (4 weeks)</description>
        <time_frame>Day 1, 14, and 28</time_frame>
        <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetics (PK) of Total PF-00547659 - Area Under the Concentration Time Profile From Time Zero to Time Tau (AUCtau)</title>
          <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. AUCtau is area under the concentration time profile from time zero to time tau, the dosing interval, where tau = 672 hours (4 weeks)</description>
          <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
          <units>Âµgâ€¢hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549500" spread="53"/>
                    <measurement group_id="O2" value="4214000" spread="31"/>
                    <measurement group_id="O3" value="10850000" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)</title>
        <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Cmax is maximum observed concentration.</description>
        <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
        <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetics (PK) of Total PF-00547659 - Maximum Observed Concentration (Cmax)</title>
          <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Cmax is maximum observed concentration.</description>
          <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
          <units>Âµg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1756" spread="45"/>
                    <measurement group_id="O2" value="10800" spread="22"/>
                    <measurement group_id="O3" value="24100" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)</title>
        <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Tmax is time for Cmax.</description>
        <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
        <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetics (PK) of Total PF-00547659 - Time for Cmax (Tmax)</title>
          <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Tmax is time for Cmax.</description>
          <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" spread="45" lower_limit="43.9" upper_limit="333"/>
                    <measurement group_id="O2" value="143" spread="22" lower_limit="44.9" upper_limit="171"/>
                    <measurement group_id="O3" value="165" spread="47" lower_limit="51.7" upper_limit="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)</title>
        <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Thalf is terminal half life.</description>
        <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
        <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetics (PK) of Total PF-00547659 - Terminal Half Life (Thalf)</title>
          <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. Thalf is terminal half life.</description>
          <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
          <units>Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.977" spread="2.8435"/>
                    <measurement group_id="O2" value="8.770" spread="2.3571"/>
                    <measurement group_id="O3" value="12.22" spread="3.8306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)</title>
        <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. CL/F is apparent clearance.</description>
        <time_frame>Day 1, 14, 28, 42, 56, 70, 84, 112, 140, 168, 196, 224 and 252</time_frame>
        <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-00547659 22.5 mg</title>
            <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 75 mg</title>
            <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 225 mg</title>
            <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Pharmacokinetics (PK) of Total PF-00547659 - Apparent Clearance (CL/F)</title>
          <description>The Pharmacokinetics (PK) of total PF-00547659 was characterized using a population PK approach. PK parameters including but not limited to AUC, CL and half life were estimated using data pooled from both typical and additional PK groups. CL/F is apparent clearance.</description>
          <population>All participants who received at least 1 dose of investigational product and had data for at least 1 PK concentration were included in the PK concentration analysis.</population>
          <units>mL/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.54" spread="63"/>
                    <measurement group_id="O2" value="16.79" spread="28"/>
                    <measurement group_id="O3" value="16.38" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PF-00547659 22.5 mg</title>
          <description>PF-00547659 22.5 mg delivered subcutaneously (SC), 3 doses separated by 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>PF-00547659 75 mg</title>
          <description>PF-00547659 75 mg delivered SC, 3 doses separated by 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>PF-00547659 225 mg</title>
          <description>PF-00547659 225 mg delivered SC, 3 doses separated by 4 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo delivered SC, 3 doses separated by 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Fistula of small intestine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Rectal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

